Ensysce Biosciences, Inc.
Ensysce Biosciences is a clinical-stage pharmaceutical company developing prescription drug candidates intended to improve safety, with a primary focus on opioid pain medicines and opioid use disorder products. Its development pipeline includes the TAAP platform, which uses prodrugs designed to activate in the gut, and the MPAR platform, which combines TAAP prodrugs with nafamostat to limit opioid activation when multiple doses are taken. Its lead candidate, PF614, is a TAAP oxycodone prodrug being developed for acute or chronic pain. PF614-MPAR combines PF614 with nafamostat and is being studied for overdose protection. Ensysce also has other TAAP and MPAR opioid and amphetamine candidates in its portfolio. The company is based in La Jolla, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ENSC in the last 7 days.
No SEC Form 4 filings for $ENSC in the last 30 days.
See all $ENSC insider activity →Ensysce Biosciences (ENSC) announced leadership changes. CEO Lynn Kirkpatrick will become COO after the December 14, 2026 annual meeting. President James Morrisson will assume the CEO role. Director Will Chang intends to resign. Kirkpatrick's employment offer letter was amended to reflect the title change and severance terms.
Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Ensysce Biosciences Inc. (the “Company”) has been advised by Mr. Will Chang, a member of the Company’s Board of Directors, t
Cantor Fitzgerald initiated coverage of Ensysce Biosciences with an Overweight rating and a $2.00 price target, implying a 297.7% upside from the Oct 19 close of $0.50. The analyst highlights the company's potential in treating chronic pain with its CY200 formulation, citing strong clinical rationale and promising early data.
Recent ENSC coverage spans corporate actions, financial news and regulation.
Leadership transition is likely to be viewed as a governance and execution continuity signal, but it is not tied to new financial guidance or operational milestones in the article.
Board and C-suite succession details can shift governance expectations and near-term execution risk, especially with a scheduled CEO transition.
Cantor Fitzgerald initiated coverage of Ensysce Biosciences with an Overweight rating and a $2.00 price target, implying a 297.7% upside from the Oct 19 close of $0.50. The analyst highlights the company's potential in treating chronic pain with its CY200 formulation, citing strong clinical rationale and promising early data.
The FDA hearing participation highlights regulatory engagement and may improve investor sentiment, but no immediate catalyst for price movement.
Milestone may boost investor confidence and support near‑term price appreciation.
AlphAI scores every news story that mentions ENSC with an AI model for sentiment and relevance, and aggregates insider trades from Ensysce Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ensysce Biosciences (ENSC) announced leadership changes. CEO Lynn Kirkpatrick will become COO after the December 14, 2026 annual meeting. President James Morrisson will assume the CEO role. Director Will Chang intends to resign. Kirkpatrick's employment offer letter was amended to reflect the title change and severance terms.
Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Ensysce Biosciences Inc. (the “Company”) has been advised by Mr. Will Chang, a member of the Company’s Board of Directors, t
Cantor Fitzgerald initiated coverage of Ensysce Biosciences with an Overweight rating and a $2.00 price target, implying a 297.7% upside from the Oct 19 close of $0.50. The analyst highlights the company's potential in treating chronic pain with its CY200 formulation, citing strong clinical rationale and promising early data.
Ensysce Biosciences (ENSC) announced that its Chief Medical Officer, Richard Langford, will speak at an FDA hearing on September 14, 2026, about the future therapeutic use of psychedelic drugs. The hearing focuses on data standards and access considerations, aligning with Executive Order 14401. Ensysce, which acquired Cy Biopharma in August 2026, is developing psychedelic-based therapies for Complex Regional Pain Syndrome Type 1 (CRPS).
Ensysce Biosciences (NASDAQ: ENSC) completed enrollment in the final stage of its PF614-MPAR-102 clinical study, evaluating its opioid overdose-protection technology. The study, supported by the National Institute on Drug Abuse, aims to characterize the drug's protective profile. Ensysce's CEO called this a milestone in addressing opioid overdose risk. The company is a clinical-stage biotech developing pain management and CNS therapies. According to Ensysce, nearly 80,000 people in the U.S. die
Ensys (ENSC) received Nasdaq notices confirming compliance with the $2.5M equity rule but faces ongoing reviews on bid price and change-of-control requirements. The company was granted an extension to February 22, 2027, to address the bid-price issue and will submit an initial listing application due to its August acquisition of Cy.
Ensysce Biosciences (ENSC) has met Nasdaq's minimum equity requirement and requested a second 180-day grace period for its bid price. The company raised $21M from its Series C financing and awaits Nasdaq's confirmation. Delisting risk is reduced, but the second tranche is contingent on a clinical milestone.
Ensysce Biosciences raised $21M in the first tranche of its Series C financing, issuing 120,260 shares for a total $43M. The company meets Nasdaq equity rules and seeks a second 180-day grace period. It believes it has at least $2.5M in stockholders' equity, satisfying Nasdaq's requirements.
Ensysce Biosciences ended Q2 2026 with $676,704 in cash but secured $31M post-quarter from acquiring Cy Biopharma and related financings. The deal adds CY200, a neuroplastogenic candidate for CRPS, as the lead asset. Proceeds will fund CY200's Phase 2 trial and existing opioid programs. Ensysce's cash runway extends into late 2027, with a potential $38.6M tranche for 2028 if milestones are met. Q2 R&D expenses rose to $2.47M, widening the net loss to $2.57M.
Ensysce Biosciences (ENSC) completed a $77.2M private securities raise, with $38.6M contingent on future events. The offering involved equity and securities acquired via rights, with UBS and Cantor Fitzgerald as brokers. The company declined to disclose revenue.
